Research digest: SGLT2 inhibition in kidney and liver disease

Data continue to accumulate about the clinical benefits of sodium-glucose co-transporter-2 (SGLT2) inhibition in high-risk populations. The CREDENCE trial results provide valuable new insights in patients with type 2 diabetes and chronic kidney disease. 4401 patients with an estimated glomerular filtration rate (eGFR) of 30–89 mL/min per 1·73m2 plus clinically significant proteinuria were randomly assigned to daily canagliflozin or placebo and...